Patents by Inventor Jan Vagberg

Jan Vagberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20230322807
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 12, 2023
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom
    Patent number: 11691988
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: July 4, 2023
    Assignee: Kancera AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11660303
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 30, 2023
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20230068240
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 2, 2023
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom
    Patent number: 11542281
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: January 3, 2023
    Assignee: KANCERA AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1
    Patent number: 11339183
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 24, 2022
    Assignee: KANCERA AB
    Inventors: Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Mattias Jönsson
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210340167
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 4, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210292349
    Abstract: There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 5, 2019
    Publication date: September 23, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20210267994
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 2, 2021
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20210188873
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 15, 2019
    Publication date: June 24, 2021
    Inventors: Jan Vågberg, Styrbjörn Byström
  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11008318
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 18, 2021
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 10550113
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 4, 2020
    Assignee: KANCERA AB
    Inventors: Hakan Mellstedt, Styrbjorn Bystrom, Jan Vagberg, Elisabeth Olsson
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20200024272
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 23, 2020
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
    Patent number: 10512634
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 24, 2019
    Assignee: KANCERA AB
    Inventors: Johan Schultz, Jan Vågberg, Elisabeth Olsson, Katarina Färnegårdh, Mattias Jönsson, Kristin Hammer, Lars Krüger
  • BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY
    Publication number: 20180110755
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: May 11, 2015
    Publication date: April 26, 2018
    Inventors: Johan SCHULTZ, Jan VÅGBERG, Elisabeth OLSSON, Katarina FÄRNEGÅRDH, Mattias JÖNSSON, Kristin HAMMER, Lars KRÜGER
  • 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20180002329
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 4, 2018
    Inventors: Hakan MELLSTEDT, Styrbjorn BYSTROM, Jan VAGBERG, Elisabeth OLSSON
  • 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
    Patent number: 9675596
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—; —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 13, 2017
    Assignee: Baltic Bio AB
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20160128993
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—; —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Application
    Filed: October 14, 2015
    Publication date: May 12, 2016
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer
    Patent number: 9162994
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—, —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: October 20, 2015
    Assignee: BETAGENON AB
    Inventors: Jacob Westman, Allan Hallett, Jan Vågberg
  • 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20120183537
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—, —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Application
    Filed: July 8, 2010
    Publication date: July 19, 2012
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg